NEW YORK (GenomeWeb News) – The Dana-Farber Cancer Institute will use cross-species genomic analysis and validation testing in a cancer drug collaboration with Merck, the Institute said today.
 
Under the agreement, Merck will provide the Center for Applied Cancer Science at Dana-Farber with up-front and research support funding and with milestone and royalty payments if a drug is approved for marketing. CACS will retain the right to develop its antibodies independently from the collaboration with Merck.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.